Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus
SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will utilize the Therapeutic Development Services funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to conduct further preclinical studies of AB-SA01. The Therapeutic Development Services program funds the provision of preclinical services for selected companies and researchers in order to advance development of promising interventional agents.
“We are pleased and encouraged by the support from the NIAID and its commitment to studying the role of bacteriophage in combating infectious diseases,” said Paul C. Grint, M.D., CEO of AmpliPhi Biosciences. “This service will help support the development of bacteriophages as a much needed treatment for antibiotic-resistant infections.”
AB-SA01 is a 3-phage investigational therapeutic being developed for treatment of serious and drug-resistant Staphylococcus aureus (S. aureus) infections. In preclinical studies, AB-SA01 demonstrated broad activity against more than 96% of global S. aureus clinical isolates, including multidrug-resistant forms. AB-SA01 has completed two Phase 1 studies and has also been administered to patients under compassionate use guidelines in the U.S. and Australia for treatment of serious and life-threatening S. aureus infections … read more